Matches in SemOpenAlex for { <https://semopenalex.org/work/W2947029248> ?p ?o ?g. }
Showing items 1 to 91 of
91
with 100 items per page.
- W2947029248 abstract "5044 Background: The Phase 3 ARCHES trial (NCT02677896) evaluated the efficacy and safety of ENZ + androgen deprivation therapy (ADT) vs placebo (PBO) + ADT in 1150 men with mHSPC. Here we report patient-reported outcome (PRO) data using Functional Assessment of Cancer Therapy-Prostate (FACT-P) and Brief Pain Inventory Short Form (BPI-SF). Methods: FACT-P and BPI-SF were assessed at baseline (BL), week (wk) 13, and then every 12 wks until disease progression. Longitudinal changes were assessed using mean scores and mixed-model repeated measures; lower BPI-SF scores represent less pain/interference; higher FACT-P scores represent better HRQoL. Time from BL to first deterioration in PRO score was assessed by Kaplan-Meier estimates and Cox proportional hazards models. Clinically meaningful difference was defined by change from baseline ≥10 for FACT-P total and ≥2 for worst pain/severity. Results: PRO instrument completion rates were high (88−96%) up to wk 73. At BL, men in both arms were generally asymptomatic and reported good HRQoL (FACT-P total: ENZ + ADT, 113.9; PBO + ADT, 112.7) and low pain (worst pain [item 3]: ENZ + ADT, 1.80; PBO + ADT, 1.77). HRQoL and pain scores remained stable over time and there were no clinically meaningful differences between groups in change from BL to wk 73. The proportion of men with no change or improvement in PRO scores (67–88%) was similar in both groups at all time points up to wk 73. There was no significant difference between arms for time to deterioration in FACT-P total (HR 0.90 [95% CI] (0.74, 1.09); p = 0.2998). ENZ + ADT significantly delayed time to pain progression for worst pain (HR 0.82 [0.69, 0.98]; p = 0.0322) and pain severity (HR 0.79 [0.65, 0.97]; p = 0.0209) vs PBO + ADT. Conclusions: Men with mHSPC were generally asymptomatic and had high levels of HRQoL and low levels of pain at BL, likely due to most men initiating ADT several months prior to study entry. No clinically meaningful differences in HRQoL were observed between ENZ and PBO. The prolongation in radiographic progression-free survival observed with ENZ + ADT was accompanied by a significantly prolonged time to progression of worst pain and pain severity vs PBO + ADT. Clinical trial information: NCT02677896." @default.
- W2947029248 created "2019-06-07" @default.
- W2947029248 creator A5001736199 @default.
- W2947029248 creator A5018831568 @default.
- W2947029248 creator A5019977496 @default.
- W2947029248 creator A5020692060 @default.
- W2947029248 creator A5038489185 @default.
- W2947029248 creator A5042337225 @default.
- W2947029248 creator A5053749991 @default.
- W2947029248 creator A5069289897 @default.
- W2947029248 creator A5071060598 @default.
- W2947029248 creator A5078252133 @default.
- W2947029248 creator A5086583298 @default.
- W2947029248 creator A5088312939 @default.
- W2947029248 creator A5089739735 @default.
- W2947029248 date "2019-05-20" @default.
- W2947029248 modified "2023-09-26" @default.
- W2947029248 title "Health-related quality of life (HRQoL) and pain progression with enzalutamide (ENZ) in metastatic hormone-sensitive prostate cancer (mHSPC) from the ARCHES study." @default.
- W2947029248 doi "https://doi.org/10.1200/jco.2019.37.15_suppl.5044" @default.
- W2947029248 hasPublicationYear "2019" @default.
- W2947029248 type Work @default.
- W2947029248 sameAs 2947029248 @default.
- W2947029248 citedByCount "3" @default.
- W2947029248 countsByYear W29470292482021 @default.
- W2947029248 crossrefType "journal-article" @default.
- W2947029248 hasAuthorship W2947029248A5001736199 @default.
- W2947029248 hasAuthorship W2947029248A5018831568 @default.
- W2947029248 hasAuthorship W2947029248A5019977496 @default.
- W2947029248 hasAuthorship W2947029248A5020692060 @default.
- W2947029248 hasAuthorship W2947029248A5038489185 @default.
- W2947029248 hasAuthorship W2947029248A5042337225 @default.
- W2947029248 hasAuthorship W2947029248A5053749991 @default.
- W2947029248 hasAuthorship W2947029248A5069289897 @default.
- W2947029248 hasAuthorship W2947029248A5071060598 @default.
- W2947029248 hasAuthorship W2947029248A5078252133 @default.
- W2947029248 hasAuthorship W2947029248A5086583298 @default.
- W2947029248 hasAuthorship W2947029248A5088312939 @default.
- W2947029248 hasAuthorship W2947029248A5089739735 @default.
- W2947029248 hasConcept C121608353 @default.
- W2947029248 hasConcept C126322002 @default.
- W2947029248 hasConcept C142724271 @default.
- W2947029248 hasConcept C143998085 @default.
- W2947029248 hasConcept C159110408 @default.
- W2947029248 hasConcept C204787440 @default.
- W2947029248 hasConcept C27081682 @default.
- W2947029248 hasConcept C2776551883 @default.
- W2947029248 hasConcept C2777899217 @default.
- W2947029248 hasConcept C2779951463 @default.
- W2947029248 hasConcept C2780192828 @default.
- W2947029248 hasConcept C61367390 @default.
- W2947029248 hasConcept C71924100 @default.
- W2947029248 hasConceptScore W2947029248C121608353 @default.
- W2947029248 hasConceptScore W2947029248C126322002 @default.
- W2947029248 hasConceptScore W2947029248C142724271 @default.
- W2947029248 hasConceptScore W2947029248C143998085 @default.
- W2947029248 hasConceptScore W2947029248C159110408 @default.
- W2947029248 hasConceptScore W2947029248C204787440 @default.
- W2947029248 hasConceptScore W2947029248C27081682 @default.
- W2947029248 hasConceptScore W2947029248C2776551883 @default.
- W2947029248 hasConceptScore W2947029248C2777899217 @default.
- W2947029248 hasConceptScore W2947029248C2779951463 @default.
- W2947029248 hasConceptScore W2947029248C2780192828 @default.
- W2947029248 hasConceptScore W2947029248C61367390 @default.
- W2947029248 hasConceptScore W2947029248C71924100 @default.
- W2947029248 hasLocation W29470292481 @default.
- W2947029248 hasOpenAccess W2947029248 @default.
- W2947029248 hasPrimaryLocation W29470292481 @default.
- W2947029248 hasRelatedWork W2035270907 @default.
- W2947029248 hasRelatedWork W2237546121 @default.
- W2947029248 hasRelatedWork W2247430959 @default.
- W2947029248 hasRelatedWork W2346356663 @default.
- W2947029248 hasRelatedWork W2588179146 @default.
- W2947029248 hasRelatedWork W2898219316 @default.
- W2947029248 hasRelatedWork W2898376762 @default.
- W2947029248 hasRelatedWork W2913942481 @default.
- W2947029248 hasRelatedWork W2921118547 @default.
- W2947029248 hasRelatedWork W2921268519 @default.
- W2947029248 hasRelatedWork W2946985555 @default.
- W2947029248 hasRelatedWork W2963794755 @default.
- W2947029248 hasRelatedWork W2978582613 @default.
- W2947029248 hasRelatedWork W2979628359 @default.
- W2947029248 hasRelatedWork W3007776535 @default.
- W2947029248 hasRelatedWork W3023106870 @default.
- W2947029248 hasRelatedWork W3032053457 @default.
- W2947029248 hasRelatedWork W3043711453 @default.
- W2947029248 hasRelatedWork W3157858132 @default.
- W2947029248 hasRelatedWork W3168706108 @default.
- W2947029248 isParatext "false" @default.
- W2947029248 isRetracted "false" @default.
- W2947029248 magId "2947029248" @default.
- W2947029248 workType "article" @default.